Deputy Director Gordon Johnston will depart from OGD Jan. 1 following acceptance of an associate position at Lachman Consultant Services. Johnston will be joining former OGD Deputy Director and Lachman VP Robert Pollock. OGD Labeling and Program Support Division Director Jerry Phillips begins a new post at the end of November as associate director for medication errors in the newly established Office of Post-marketing Drug Risk Assessment ("The Pink Sheet" Nov. 2, p. 6). Phillip's vacated position will be filled by Consumer Safety Officer Robert West. Division of Chemistry II Director Frank Holcombe will become OGD acting associate director for chemistry, and will be replaced by Florence Fong

Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.

In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."